Thrombotic antiphospholipid syndrome: From guidelines to clinical management.
Review published in Medicina clinica (2024)
Abstract
Thrombotic manifestations, mainly venous thromboembolism (VTE) and stroke, are the most common and potentially life-threatening presentations of antiphospholipid syndrome (APS). The management of APS requires the assessment of the antiphospholipid antibodies (aPL) profile, of concurrent systemic lupus erythematosus or other systemic autoimmune diseases and the presence of risk factors for cardiovascular disease and bleeding. Anticoagulation with vitamin K antagonists (VKA) remains the cornerstone of therapy for thrombotic APS. As platelets play a central role in APS, low-dose aspirin is the first option for primary thromboprophylaxis in asymptomatic aPL carriers, and also plays a role as combination therapy with VKAs in arterial thrombosis. Treatment with direct oral anticoagulants (DOACs) could be considered in certain low-risk situations, although they are not recommended in patients with arterial thrombosis or triple positive aPL. Adjuvant therapies such as hydroxychloroquine and statins may be useful in complex settings such as thrombotic recurrences or high risk of bleeding. In this article, we review the evidence and the recommendations of the guidelines for the treatment of APS, and provide a critical and practical approach of its management from our clinical perspective.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Thrombotic manifestations, mainly venous thromboembolism (VTE) and stroke, are the most common and potentially life-threatening presentations of antiphospholipid syndrome (APS). The management of APS requires the assessment of the antiphospholipid antibodies (aPL) profile, of concurrent systemic...
Por qué esto importa para la hirudoterapia
Esta revisión abarca el tratamiento del síndrome antifosfolípido trombótico, analizando la anticoagulación con antagonistas de la vitamina K como pilar fundamental, con funciones para la aspirina, los anticoagulantes orales directos en casos seleccionados, y terapias adyuvantes como la hidroxicloroquina y las estatinas. Es relevante para el ámbito de la ASH solo en el sentido amplio de la terapéutica anticoagulante —el espacio clínico compartido por los derivados de la hirudina. El resumen no hace referencia alguna a sanguijuelas, hirudoterapia o agentes basados en hirudina. Su conexión con la hirudoterapia es indirecta y limitada.
Citación
Thrombotic antiphospholipid syndrome: From guidelines to clinical management.
Paredes-Ruiz et al. · Medicina clinica, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026